Neoadjuvant Erlotinib Treatment in Patients with Resectable Non-Small Cell Lung Carcinoma

被引：0
作者：
Van Gool, Matthijs [1 ]
Kiomp, Houke [1 ]
机构：
[1] NKI AVL, Amsterdam, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
neoadjuvant; Surgery; EGFR-TKI;
D O I：
10.1016/j.jtho.2016.11.834
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.05-049
引用
收藏
页码：S644 / S645
页数：2
相关论文
共 50 条
  • [41] Neoadjuvant Targeted Therapy for Resectable ALK-fusion Locally Advanced Non-small Cell Lung Cancer
    Zhao, D.
    Wu, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S295 - S296
  • [42] CHEMOTHERAPY VERSUS ERLOTINIB IN THE SECOND LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Fiala, Ondrej
    Pesek, Milos
    Krejci, Jana
    Sticha, Michal
    Minarik, Marek
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1259 - S1260
  • [43] Real-World Outcomes of Patients with Resectable Early-Stage Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemoimmunotherapy
    Hazim, A.
    Xiao, A.
    Singh, A.
    Chung, K.
    dos Santos, P. A. Reck
    D'Cunha, J.
    Shanshal, M.
    Dimou, A.
    Parikh, K.
    Lou, Y.
    Manochakian, R.
    Leventakos, K.
    Molina, J.
    Mansfield, A.
    Ernani, V.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S546 - S547
  • [44] The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
    Dunne, Elizabeth G.
    Fick, Cameron N.
    Isbell, James M.
    Chaft, Jamie E.
    Altorki, Nasser
    Park, Bernard J.
    Spicer, Jonathan
    Forde, Patrick M.
    Gomez, Daniel
    Iyengar, Puneeth
    Harpole Jr, David H.
    Stinchcombe, Thomas E.
    Liberman, Moishe
    Bott, Matthew J.
    Adusumilli, Prasad S.
    Huang, James
    Rocco, Gaetano
    Jones, David R.
    ANNALS OF THORACIC SURGERY, 2024, 118 (01) : 119 - 129
  • [45] SURGICAL OUTCOME OF ELDERLY PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA
    Gudbjartsson, Tomas
    Baldvinsson, Kristjan
    Orrason, Andri W.
    Thorsteinsson, Hunbogi
    Sigurdsson, Martin I.
    Jonsson, Steinn
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S517 - S517
  • [46] Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)
    Hong, M. H.
    Ahn, B.
    Kim, H. R.
    Lim, S. M.
    Lee, S.
    Park, S. Y.
    Lee, C. Y.
    Lee, J. G.
    Kim, D. J.
    Lee, S. H.
    Yoon, H. I.
    Lee, C. G.
    Cho, J.
    Shim, H. S.
    Kim, T.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S194 - S195
  • [47] Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis
    Baofeng Li
    Guangxin Zhang
    Chengyan Jin
    Yinghao Zhao
    Peiyan Hua
    Ti Tong
    Indian Journal of Surgery, 2023, 85 : 584 - 596
  • [48] Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis
    Li, Baofeng
    Zhang, Guangxin
    Jin, Chengyan
    Zhao, Yinghao
    Hua, Peiyan
    Tong, Ti
    INDIAN JOURNAL OF SURGERY, 2023, 85 (SUPPL 2) : 584 - 596
  • [49] The efficacy of neoadjuvant immunotherapy combined with chemotherapy in resectable stage IIIV non-small cell lung cancer: a preliminary study
    Tang, Chengbin
    Yang, Bo
    Liu, Yang
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (01) : 290 - 298
  • [50] Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer
    Shen, Jie
    Gu, Linping
    Qi, Yuwen
    Yao, Yaxian
    Lu, Shun
    Chen, Zhiwei
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345